CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 236 enrolled
Drug / intervention
Duloxetine +1 moredrug
Likely dose
Duloxetine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00424593
NCT00424593Phase 3Completed

Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain

Eli Lilly and Company·interventional·Posted Jan 19, 2007·Updated Nov 20, 2009

In Brief

A Phase 3 clinical trial evaluating Duloxetine and Placebo for Back Pain Without Radiation. Completed, enrolled 236 participants across 17 sites in 5 countries.

Detailed Summary

The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition. Whether duloxetine once daily can help patients with Chronic Low Back Pain. Patients who do not have their pain reduced by at least 30% by week 7 will be given 120 mg dose for the duration of the study. After the 13 week double blind period, patients randomized to placebo will switch to duloxetine 60 mg or 120 mg in the 41-week extension period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil, France, Germany, Mexico, Netherlands
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 19, 2007
Enrollment StartJan 1, 2007
Primary CompletionDec 1, 2007
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.5 years ago

Interventions

Duloxetinedrug

30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase

Placebodrug

every day (QD), by mouth (PO), 13 weeks